| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CD90 |
| Uniprot No | P04216 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 20-130aa |
| 氨基酸序列 | QKVTSLTACLVDQSLRLDCRHENTSSSPIQYEFSLTRETKKHVLFGTVGV PEHTYRSRTNFTSKYNMKVLYLSAFTSKDEGTYTCALHHSGHSPPISSQN VTVLRDKLVKCHHHHHH |
| 预测分子量 | 13 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下为基于CD90(Thy-1)重组蛋白研究领域的**示例性参考文献**(内容为领域知识概括，非真实文献，建议通过学术数据库查询具体论文)：
---
1. **文献名称**：*Recombinant CD90/Thy-1 Protein Suppresses Hepatic Stellate Cell Activation via TGF-β/Smad Signaling*
**作者**：Zhang Y et al.
**摘要**：研究通过哺乳动物细胞表达系统纯化CD90重组蛋白，发现其通过抑制TGF-β/Smad通路减少肝星状细胞活化，提示其在抗肝纤维化治疗中的潜在应用。
2. **文献名称**：*Thy-1 Recombinant Protein Attenuates Lung Fibrosis through Modulation of Integrin Signaling*
**作者**：Smith JL et al.
**摘要**：利用原核系统表达CD90重组蛋白，实验表明其通过阻断成纤维细胞整合素αvβ3相互作用，抑制胶原沉积，为肺纤维化治疗提供新靶点。
3. **文献名称**：*CD90-Fc Fusion Protein Inhibits Tumor Angiogenesis by Targeting Endothelial Cell Migration*
**作者**：Wang H et al.
**摘要**：构建CD90-Fc重组融合蛋白，证实其通过竞争性结合VEGF受体抑制内皮细胞迁移和血管生成，为抗肿瘤治疗提供策略。
4. **文献名称**：*Recombinant Thy-1 Protein Modulates T-cell Synapse Formation and Immune Response*
**作者**：Lee K et al.
**摘要**：研究CD90重组蛋白对T细胞免疫突触的影响，发现其通过调控细胞膜脂筏结构增强T细胞活化，为免疫调节剂开发提供依据。
---
**建议**：可通过PubMed、Web of Science等平台，以关键词“CD90 recombinant protein”“Thy-1 expression”“CD90 fibrosis/cancer”检索最新文献，重点关注**功能机制**或**治疗应用**类研究。
CD90 (Thy-1), a glycosylphosphatidylinositol (GPI)-anchored cell membrane protein, belongs to the immunoglobulin (Ig) superfamily. Initially identified as a thymocyte antigen in mice, it is encoded by the *THY1* gene in humans. Structurally, CD90 contains a single Ig-like variable (V) domain linked to the membrane via a GPI anchor, enabling dynamic localization in lipid rafts. It is evolutionarily conserved, with ~70% amino acid homology between human and mouse isoforms. CD90 is expressed in various cell types, including fibroblasts, neurons, endothelial cells, and stem cells, playing roles in cell adhesion, migration, signaling, and tissue development.
Its biological functions are context-dependent. In neurons, CD90 modulates synaptic plasticity and neurite outgrowth. In mesenchymal stem cells, it serves as a surface marker and regulates differentiation. CD90 also participates in immune regulation by interacting with integrins and lectins, influencing T-cell activation and inflammation. Notably, CD90 is implicated in pathological processes: it promotes fibrosis by activating fibroblasts in chronic diseases, and exhibits dual roles in cancer—acting as a tumor suppressor in some malignancies while enhancing metastasis in others through epithelial-mesenchymal transition (EMT).
Recombinant CD90 protein is produced using expression systems (e.g., *E. coli*, mammalian cells) to study its structure-function relationships, ligand interactions, and signaling pathways. It enables *in vitro* assays to dissect its role in cell-matrix interactions, immune modulation, and disease mechanisms. Researchers also utilize recombinant CD90 to generate antibodies, develop drug delivery platforms, or engineer biomimetic matrices for regenerative medicine. Its purity and consistency make it advantageous over native protein isolation, particularly for mechanistic studies requiring standardized reagents. Ongoing research focuses on leveraging CD90's multifunctionality for therapeutic targeting in fibrosis, cancer, and neurodegenerative disorders.
×
